Epithalon vs NAD+: Very Different Evidence Behind a Shared Label

The short answer

NAD+ is nicotinamide adenine dinucleotide, a coenzyme involved in redox reactions across cellular metabolism. Its role is established biochemistry, and the research question is about modulating its availability rather than whether it matters. Epithalon is a synthetic tetrapeptide studied in a much smaller literature, much of it Russian-language, with claims often reported at a level the underlying evidence does not support.

NAD+: established biochemistry

NAD+ participates in redox reactions throughout metabolism and is a substrate for several enzyme families. None of that is contested - it is textbook cell biology. The active research question is narrower than the marketing suggests: what happens when availability is altered, and by what route. Being biochemically central is not the same as being an established intervention.

Epithalon: a narrow literature

Epithalon is a synthetic tetrapeptide developed within a specific research programme, and much of the published work on it comes from that same tradition. Independent replication outside it is limited, and a good deal of the literature is Russian-language and less represented in English-language indexes. Claims about telomere biology in particular are frequently reported at a confidence the published record does not carry.

Reading the comparison honestly

Grouping these two together reflects how they are marketed, not what is known about them. A researcher should regard the NAD+ literature and the epithalon literature as being at completely different stages of maturity, and should be especially careful with secondary sources that present epithalon findings without noting the narrowness of their origin.